An insider's perspective on FDA approval of aducanumab
Abstract Introduction Aducanumab was approved in 2021 by the US Food and Drug Administration (FDA) under the accelerated approval pathway. Since then, there have been many misconceptions about the approval decision despite multiple publications from the FDA to explain the rationale. Methods Even tho...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Online Access: | https://doi.org/10.1002/trc2.12382 |